Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Mar 13, 2024 (filed on Mar 13, 2024)Insider Name:Artal International S.C.A.Ownership Type:Indirect OwnershipSecurities:Series A Convertible Preferred StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:1,150,922Price:$108.50
-
Feb 28, 2024 (filed on Feb 29, 2024)Insider Name:Alexander KristenOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-15,927Price:--
-
Feb 28, 2024 (filed on Feb 29, 2024)Insider Name:Alexander KristenOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-10,616Price:--
-
Feb 28, 2024 (filed on Feb 29, 2024)Insider Name:Alexander KristenOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-2,700Price:--
-
Feb 28, 2024 (filed on Feb 29, 2024)Insider Name:Alexander KristenOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-11,793Price:$2.62
-
Feb 28, 2024 (filed on Feb 29, 2024)Insider Name:Alexander KristenOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:15,927Price:--
-
Feb 28, 2024 (filed on Feb 29, 2024)Insider Name:Alexander KristenOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:10,616Price:--
-
Feb 28, 2024 (filed on Feb 29, 2024)Insider Name:Alexander KristenOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:2,700Price:--
-
Feb 28, 2024 (filed on Feb 29, 2024)Insider Name:Wade Jeffrey LOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-49,113Price:--
-
Feb 28, 2024 (filed on Feb 29, 2024)Insider Name:Wade Jeffrey LOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-37,274Price:--
Filings by filing date
-
Mar 13, 2024 (filed on Mar 13, 2024)Insider Name:Artal International S.C.A.Ownership Type:Indirect OwnershipSecurities:Series A Convertible Preferred StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:1,150,922Price:$108.50
-
Feb 28, 2024 (filed on Feb 29, 2024)Insider Name:Alexander KristenOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-15,927Price:--
-
Feb 28, 2024 (filed on Feb 29, 2024)Insider Name:Alexander KristenOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-10,616Price:--
-
Feb 28, 2024 (filed on Feb 29, 2024)Insider Name:Alexander KristenOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-2,700Price:--
-
Feb 28, 2024 (filed on Feb 29, 2024)Insider Name:Alexander KristenOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-11,793Price:$2.62
-
Feb 28, 2024 (filed on Feb 29, 2024)Insider Name:Alexander KristenOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:15,927Price:--
-
Feb 28, 2024 (filed on Feb 29, 2024)Insider Name:Alexander KristenOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:10,616Price:--
-
Feb 28, 2024 (filed on Feb 29, 2024)Insider Name:Alexander KristenOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:2,700Price:--
-
Feb 28, 2024 (filed on Feb 29, 2024)Insider Name:Wade Jeffrey LOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-49,113Price:--
-
Feb 28, 2024 (filed on Feb 29, 2024)Insider Name:Wade Jeffrey LOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-37,274Price:--
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 8800 TECHNOLOGY FOREST PLACE 8800 TECHNOLOGY FOREST PLACE THE WOODLANDS TX 77381 |
Tel: | N/A |
Website: | https://www.lexpharma.com |
IR: | See website |
Key People | ||
Jeffrey L. Wade President, Chief Financial Officer | Lonnel Coats Chief Executive Officer, Director | Alan J. Main Executive Vice President - Innovation and Chemical Sciences |
Brian T. Crum Senior Vice President, General Counsel | Thomas Garner Senior Vice President and Chief Commercial Officer | Craig B. Granowitz Senior Vice President, Chief Medical Officer |
Kenneth B. Kassler-Taub Senior Vice President - Regulatory and Quality Assurance | Kristen L. Alexander Vice President - Finance and Accounting | Wendy E. Mcdermott Vice President - Human Resources |
Business Overview |
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The Company pipeline includes INPEFA (sotagliflozin), LX9211, and LX9851. Sotagliflozin is an orally delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes mellitus, chronic kidney disease and other cardiovascular risk factors. LX9211 is an orally delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. The Company is conducting preclinical development of LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and tool for weight management. |
Financial Overview |
For the fiscal year ended 31 December 2023, Lexicon Pharmaceuticals Inc revenues increased from $139K to $1.2M. Net loss increased 74% to $177.1M. Revenues reflect Net product revenue increase from $0K to $1.1M. Higher net loss reflects Personnel expenses increase from $18.8M to $53M (expense), General and administrative - other increase from $22M to $51.8M (expense), Other Expenses increase from $2.8M to $13.1M (expense). |
Employees: | 285 as of Mar 21, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $330.85M as of Dec 31, 2023 |
Annual revenue (TTM): | $1.21M as of Dec 31, 2023 |
EBITDA (TTM): | -$171.20M as of Dec 31, 2023 |
Net annual income (TTM): | -$177.12M as of Dec 31, 2023 |
Free cash flow (TTM): | -$162.37M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 246,236,753 as of Mar 21, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |